摘要
Objective: To investigate factors that benefit patients with head and neck osteosarcoma( HNOS) before death. Methods: Patients admitted in our department from 2007 to 2015 who died during follow-up after surgery for HNOS were selected. Information concerning demographics,disease,treatment and follow-up were collected and analyzed. Results: A total of 77 patients died at a median age of 42 years old,of whom 33 were male and 44 female. Thirty-nine tumors were identified in the maxilla and skull base region while 38 in the mandible. Positive surgical margins were observed in 7 cases. Twenty patients received adjuvant chemotherapy,and 36 received postoperative radiotherapy. Local recurrence,as an initial cause of death,occurred in 25 cases,whilst metastasis occurred in the rest. Conclusion: Patients with HNOS benefit from negative surgical margins and adjuvant chemotherapy before death. Patients above 30 years old have longer disease-free survival,and patients with tumors of low pathological grade have longer overall survival. Tumor size and postoperative radiotherapy are negative prognostic factors. Frequent follow-up should be conducted for at least 48 postoperative months.
Objective: To investigate factors that benefit patients with head and neck osteosarcoma( HNOS) before death. Methods: Patients admitted in our department from 2007 to 2015 who died during follow-up after surgery for HNOS were selected. Information concerning demographics,disease,treatment and follow-up were collected and analyzed. Results: A total of 77 patients died at a median age of 42 years old,of whom 33 were male and 44 female. Thirty-nine tumors were identified in the maxilla and skull base region while 38 in the mandible. Positive surgical margins were observed in 7 cases. Twenty patients received adjuvant chemotherapy,and 36 received postoperative radiotherapy. Local recurrence,as an initial cause of death,occurred in 25 cases,whilst metastasis occurred in the rest. Conclusion: Patients with HNOS benefit from negative surgical margins and adjuvant chemotherapy before death. Patients above 30 years old have longer disease-free survival,and patients with tumors of low pathological grade have longer overall survival. Tumor size and postoperative radiotherapy are negative prognostic factors. Frequent follow-up should be conducted for at least 48 postoperative months.
出处
《肿瘤预防与治疗》
2018年第6期386-394,共9页
Journal of Cancer Control And Treatment
